This is a national multicentre observational study with retrospective and prospectivedata collection to assess the time to hospitalisation of patients with a confirmeddiagnosis of SARS-CoV-2 infection receiving treatment with anti-SARS-CoV-2 monoclonalantibodies.The subjects enrolled will be patients with early infection of SARS-CoV-2,paucisymptomatic, with risk factors for evolution to the severe form (according to AIFAcriteria). Also, hospitalised subjects will be enrolled to receive SARS-CoV-2 monoclonalantibodies because of negative serology (according to AIFA criteria).It is estimated to enrol about 1000 subjects.Patients will be evaluated at enrollment and 28 days following administration to collectdata on symptoms, possible hospitalization and final clinical outcome (alive withsymptoms, alive without symptoms, alive with symptoms and hospitalized or deceased).Data will be collected using a dedicated electronic Case Report Form (eCRF).